RAPT Therapeutics (RAPT) Equity Average (2020 - 2024)
Historic Equity Average for Therapeutics (RAPT) over the last 5 years, with Q3 2024 value amounting to $102.4 million.
- Therapeutics' Equity Average fell 4503.66% to $102.4 million in Q3 2024 from the same period last year, while for Sep 2024 it was $102.4 million, marking a year-over-year decrease of 4503.66%. This contributed to the annual value of $196.1 million for FY2023, which is 911.72% down from last year.
- Latest data reveals that Therapeutics reported Equity Average of $102.4 million as of Q3 2024, which was down 4503.66% from $120.0 million recorded in Q2 2024.
- Therapeutics' Equity Average's 5-year high stood at $232.8 million during Q1 2023, with a 5-year trough of $97.9 million in Q1 2021.
- Its 5-year average for Equity Average is $162.9 million, with a median of $168.5 million in 2022.
- In the last 5 years, Therapeutics' Equity Average surged by 8123.52% in 2021 and then plummeted by 4503.66% in 2024.
- Over the past 5 years, Therapeutics' Equity Average (Quarter) stood at $107.1 million in 2020, then skyrocketed by 81.24% to $194.1 million in 2021, then increased by 11.9% to $217.2 million in 2022, then dropped by 26.39% to $159.9 million in 2023, then crashed by 35.99% to $102.4 million in 2024.
- Its Equity Average stands at $102.4 million for Q3 2024, versus $120.0 million for Q2 2024 and $138.9 million for Q1 2024.